Aldeyra Therapeutics Inc (NASDAQ:ALDX) Has Decline in Shorts

June 17, 2018 - By Margaret Downey

Investors sentiment increased to 3 in 2018 Q1. Its up 1.38, from 1.62 in 2017Q4. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Millennium Mgmt Ltd Llc holds 0.01% or 753,143 shares. Hikari Ltd holds 0.1% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 107,858 shares. Knoll Capital Management Ltd Partnership stated it has 124,096 shares or 0.96% of all its holdings. 12,000 were accumulated by Drw Secs Limited Com. Element Cap Mngmt Limited Liability accumulated 0% or 16,431 shares. Stifel Financial Corporation has 10,367 shares. Peddock Cap Advsr Ltd Limited Liability Company reported 752 shares stake. Royal Bank Of Canada stated it has 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Perceptive Lc invested in 3.09M shares or 0.65% of the stock. Tower Limited Liability Corporation (Trc) holds 0% or 1,053 shares. Mangrove, a New York-based fund reported 324,019 shares. State Street Corp accumulated 25,931 shares. Stanley reported 64,029 shares stake. Geode Limited Liability holds 0% or 102,263 shares in its portfolio. Citadel Advsr Lc stated it has 11,250 shares or 0% of all its holdings.

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) registered a decrease of 19.87% in short interest. ALDX’s total short interest was 307,300 shares in June as published by FINRA. Its down 19.87% from 383,500 shares, reported previously. With 119,700 shares average volume, it will take short sellers 3 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Inc’s float is 8.49%.

The stock increased 2.31% or $0.2 during the last trading session, reaching $8.85. About 116,129 shares traded or 31.29% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since June 17, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $177.97 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 3 analyst reports since January 26, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 29 by Cantor Fitzgerald. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Tuesday, May 15 by Cantor Fitzgerald.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: